drug
Midol
Marketedupdated 3mo agoby Bionpharma Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval406 co-mentions · 166 sources
- drugOXYCODONE HYDROCHLORIDE AND IBUPROFEN383 co-mentions · 173 sources
- drugAdvil292 co-mentions · 173 sources
- drugNuprin290 co-mentions · 173 sources
- drugIBUPROFEN290 co-mentions · 173 sources
- drugHYDROCODONE BITARTRATE AND IBUPROFEN208 co-mentions · 104 sources
- drugHYDROCODONE BITARTRATE208 co-mentions · 104 sources
- drughydrocodone bitartrate ER208 co-mentions · 104 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 23 approved and 64 investigational indications.
all catalysts(38)
approval · 38
Nov 29, 2007
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Jan 4, 2008
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Sep 2, 2011
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Feb 18, 2015
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Dec 16, 2016
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Dec 16, 2016
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Dec 16, 2016
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Dec 16, 2016
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Dec 16, 2016
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Dec 16, 2016
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Aug 15, 2018
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Sep 18, 2018
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Sep 18, 2018
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Sep 21, 2018
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Sep 21, 2018
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Feb 28, 2019
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Jul 22, 2019
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Jul 22, 2019
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Oct 7, 2019
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Oct 8, 2019
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Mar 4, 2021
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Mar 4, 2021
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Apr 28, 2021
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Apr 28, 2021
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Dec 15, 2023
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Dec 15, 2023
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Dec 15, 2023
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Mar 11, 2024
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Mar 11, 2024
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Mar 27, 2024
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Mar 27, 2024
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Oct 31, 2024
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Oct 31, 2024
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Nov 21, 2024
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Nov 21, 2024
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Dec 22, 2025
approval
$BLNC
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Dec 23, 2025
approval
OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — FDA approval
Midol
→
Mar 5, 2026
approval
IBUPROFEN — FDA approval
Midol
→
Trials studying Midol
- phase3RCT, Blinded, 2-Arm Efficacy Study of IP and Placebo in Patients With Chronic Pain Related to Osteoarthritis of the Knee
- phase3A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain
- phase2Phase 2 Herniorrhaphy Study for Opioid Elimination
- phase3Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen
- phase1Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
- phase1A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
- phase3Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea
- phase3Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar Extraction
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 30, 2029
~3.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Mar 16, 2032method-of-use (U-3746)US 11806400
- Mar 16, 2032method-of-use (U-3746)US 11806400
- Mar 16, 2032method-of-use (U-2264)US 9072661
- Mar 16, 2032method-of-use (U-2266)US 9072710
- Sep 14, 2030method-of-use (U-981)US 90125084.1y
- Sep 14, 2030method-of-use (U-981)US 90125084.1y
- Sep 30, 2029method-of-use (U-981)US 87354523.1y
- Sep 30, 2029method-of-use (U-981)US 87354523.1y
- Sep 30, 2029method-of-use (U-981)US 88718103.1y
- Sep 30, 2029method-of-use (U-981)US 88718103.1y
- Sep 30, 2029method-of-use (U-1735)US 91140683.1y
- Sep 30, 2029method-of-use (U-1756)US 91384043.1y
- Sep 30, 2029method-of-use (U-1756)US 92956393.1y
- Sep 30, 2029method-of-use (U-2018)US 96492843.1y
FDA exclusivities (3)
- May 11, 2026NPPNew Product (3y)
- May 11, 2026NPPNew Product (3y)
- May 11, 2026NPPNew Product (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that